Using BMT To Cure Autoimmunity

2 June 1996

CellPro and Northwestern University Medical School have started a trial of T cell-depleted autologous bone marrow transplantation as a treatment for multiple sclerosis.

Principal investigator on the study is Richard Burt, assistant professor of medicine at NUMS and head of the allogeneic BMT program at Northwestern Memorial Hospital. Dr Burt was the first investigator in the USA to demonstrate that BMT may induce remission of MS in animal models.

NUMS' protocol for treating MS includes the use of cyclophosphamide and total body irradiation to ablate the patient's faulty immune system. Myeloablation will be followed by immune system rescue via T cell-depleted, autologous BMT. This procedure requires aspirating marrow tissue from the patient prior to myeloablation and positively selecting out stem cells with CellPro's Ceprate SC Stem Cell Concentration System.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight